Abstract
BackgroundGolimumab and certolizumab were the last original anti-TNF agents approved in Brazil for the treatment rheumatoid arthritis (RA). Recent studies indicate that certolizumab is associated with higher risk of infections...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
